Company intelligence / Profile preview

Mage Biologics Inc.

Newark, Delaware, United States

Ownership: Private
Development stage: Other

Overview

Mage Biologics has initiated a first-in-human Phase 1 study of MB‑001, an orally administered monoclonal antibody for IBD. The study is assessing safety and pharmacokinetics in healthy volunteers. The company aims to demonstrate clinical proof-of-concept for this novel oral mAb therapy designed for targeted mucosal release with minimal systemic exposure. Results are expected in the first half of 2025

Therapeutic areas: Gastroenterology
Modalities: Monoclonal antibodies (mAbs)
Industry: Biotech

Drug pipeline

3 assets

MB-001

2 more assets in the full pipeline.

Partnerships

TVM Capital Life Science (co-founder/investor/advisor)Tillotts Pharma AG (co-founder/investor/technology provider)

Beyond the preview

Go deeper on Mage Biologics Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mage Biologics Inc..